Literature DB >> 31160491

Differential Interleukin-2 Transcription Kinetics Render Mouse but Not Human T Cells Vulnerable to Splicing Inhibition Early after Activation.

Debojit Bose1, Alexander Neumann2, Bernd Timmermann3, Stefan Meinke2, Florian Heyd1.   

Abstract

T cells are nodal players in the adaptive immune response against pathogens and malignant cells. Alternative splicing plays a crucial role in T cell activation, which is analyzed mainly at later time points upon stimulation. Here we have discovered a 2-h time window early after stimulation where optimal splicing efficiency or, more generally, gene expression efficiency is crucial for successful T cell activation. Reducing the splicing efficiency at 4 to 6 h poststimulation significantly impaired murine T cell activation, which was dependent on the expression dynamics of the Egr1-Nab2-interleukin-2 (IL-2) pathway. This time window overlaps the time of peak IL-2 de novo transcription, which, we suggest, represents a permissive time window in which decreased splicing (or transcription) efficiency reduces mature IL-2 production, thereby hampering murine T cell activation. Notably, the distinct expression kinetics of the Egr1-Nab2-IL-2 pathway between mouse and human render human T cells refractory to this vulnerability. We propose that the rational temporal modulation of splicing or transcription during peak de novo expression of key effectors can be used to fine-tune stimulation-dependent biological outcomes. Our data also show that critical consideration is required when extrapolating mouse data to the human system in basic and translational research.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  RNA splicing; T cell activation; gene expression; interleukin-2

Mesh:

Substances:

Year:  2019        PMID: 31160491      PMCID: PMC6664609          DOI: 10.1128/MCB.00035-19

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  Alternative splicing networks regulated by signaling in human T cells.

Authors:  Nicole M Martinez; Qun Pan; Brian S Cole; Christopher A Yarosh; Grace A Babcock; Florian Heyd; William Zhu; Sandya Ajith; Benjamin J Blencowe; Kristen W Lynch
Journal:  RNA       Date:  2012-03-27       Impact factor: 4.942

2.  EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial origin.

Authors:  Joerg Kumbrink; Kathrin H Kirsch; Judith P Johnson
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

Review 3.  CD8 T cell quiescence revisited.

Authors:  Sara E Hamilton; Stephen C Jameson
Journal:  Trends Immunol       Date:  2012-02-21       Impact factor: 16.687

4.  IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells.

Authors:  R C Duke; J J Cohen
Journal:  Lymphokine Res       Date:  1986

5.  IL-2-mediated cell cycle progression and inhibition of apoptosis does not require NF-kappa B or activating protein-1 activation in primary human T cells.

Authors:  M Iacobelli; F Rohwer; P Shanahan; J A Quiroz; K L McGuire
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

6.  Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription.

Authors:  Samuel Collins; Lawrence A Wolfraim; Charles G Drake; Maureen R Horton; Jonathan D Powell
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

7.  Activation-induced tumor necrosis factor receptor-associated factor 3 (Traf3) alternative splicing controls the noncanonical nuclear factor κB pathway and chemokine expression in human T cells.

Authors:  Monika Michel; Ilka Wilhelmi; Astrid-Solveig Schultz; Marco Preussner; Florian Heyd
Journal:  J Biol Chem       Date:  2014-03-26       Impact factor: 5.157

8.  NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells.

Authors:  Markus Lucerna; Diana Mechtcheriakova; Alexandra Kadl; Gernot Schabbauer; Romana Schäfer; Florian Gruber; Yuri Koshelnick; Horst-Dietmar Müller; Katja Issbrücker; Matthias Clauss; Bernd R Binder; Erhard Hofer
Journal:  J Biol Chem       Date:  2002-11-08       Impact factor: 5.157

9.  CD28 costimulation regulates genome-wide effects on alternative splicing.

Authors:  Manish J Butte; Sun Jung Lee; Jonathan Jesneck; Mary E Keir; W Nicholas Haining; Arlene H Sharpe
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Distinct TCR signaling pathways drive proliferation and cytokine production in T cells.

Authors:  Clifford S Guy; Kate M Vignali; Jamshid Temirov; Matthew L Bettini; Abigail E Overacre; Matthew Smeltzer; Hui Zhang; Johannes B Huppa; Yu-Hwai Tsai; Camille Lobry; Jianming Xie; Peter J Dempsey; Howard C Crawford; Iannis Aifantis; Mark M Davis; Dario A A Vignali
Journal:  Nat Immunol       Date:  2013-02-03       Impact factor: 25.606

View more
  4 in total

Review 1.  Artificial Intelligence in Bulk and Single-Cell RNA-Sequencing Data to Foster Precision Oncology.

Authors:  Marco Del Giudice; Serena Peirone; Sarah Perrone; Francesca Priante; Fabiola Varese; Elisa Tirtei; Franca Fagioli; Matteo Cereda
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

2.  TGFβ limits Myc-dependent TCR-induced metabolic reprogramming in CD8+ T cells.

Authors:  Helen Carrasco Hope; Gabriella Pickersgill; Pierpaolo Ginefra; Nicola Vannini; Graham P Cook; Robert J Salmond
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

3.  Recruitment of a splicing factor to the nuclear lamina for its inactivation.

Authors:  Karen Vester; Marco Preußner; Nicole Holton; Suihan Feng; Carsten Schultz; Florian Heyd; Markus C Wahl
Journal:  Commun Biol       Date:  2022-07-22

Review 4.  The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas.

Authors:  Pinelopi I Artemaki; Petros A Letsos; Ioanna C Zoupa; Katerina Katsaraki; Paraskevi Karousi; Sotirios G Papageorgiou; Vasiliki Pappa; Andreas Scorilas; Christos K Kontos
Journal:  Biomedicines       Date:  2021-03-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.